CN111704641B - Iridoid glycoside compound and preparation method and application thereof - Google Patents

Abstract

The invention discloses an iridoid glycoside compound which is a new chemical component found in gardenia. The invention also carries out structural identification on the compound separated by the method through physicochemical properties and modern spectral means. The invention also utilizes an activity screening system such as an LPS (LPS) -induced RAW264.7 cell inflammation model and the like to carry out activity evaluation, and finds that the compound has a certain protection effect on a mouse macrophage system RAW264.7 and can obviously inhibit PGE (platelet-rich antigen)₂Showing strong anti-inflammatory action.

Description

Iridoid glycoside compound and preparation method and application thereof

Technical Field

The invention relates to the technical field of medicines, and particularly relates to a novel compound and a preparation method and application thereof.

Background

Gardenia jasminoides Ellis is derived from dried mature fruits of Gardenia jasminoides Ellis of Gardenia of Rubiaceae (Rubiaceae), belongs to the first batch of medicinal and edible resources issued by Ministry of health, and has the effects of protecting liver, promoting bile flow, lowering blood pressure, tranquilizing, stopping bleeding, reducing swelling and the like. Is used for treating icteric hepatitis, sprain, contusion, hypertension, diabetes and other diseases in traditional Chinese medicine clinic.

Anti-inflammatory drugs in clinical treatment are the second largest class of drugs next to anti-infective drugs, including steroidal anti-inflammatory drugs (SAID) and non-steroidal anti-inflammatory drugs (NSAID). However, because of the strong toxic and side effects of many synthetic drugs, people pay more and more attention to the development of anti-inflammatory drugs from natural drugs.

Disclosure of Invention

The invention aims to carry out more intensive research on active ingredients of gardenia and find out active ingredients which play certain roles.

In view of the above, the present invention provides an iridoid glycoside compound or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, prodrug molecule, metabolite thereof, wherein the compound has the following structure, and the structure of the compound is shown in formula I:

another object of the present invention is to provide a method for preparing the above compound, which comprises the steps of:

step 1: taking 40kg of gardenia dry medicinal materials, carrying out reflux extraction by 50-70% ethanol, and removing a solvent to obtain a total extract;

step 2: dissolving the total extract in water, separating by macroporous adsorption resin column chromatography, eluting with water, 25-35% ethanol, 45-55% ethanol, 65-75% ethanol and 90-100% ethanol in sequence, collecting eluates respectively, and concentrating under reduced pressure until no alcohol smell exists to obtain a water elution part, a 25-35% ethanol elution part, a 45-55% ethanol elution part, a 65-75% ethanol elution part and a 90-100% ethanol elution part;

and step 3: separating the 25-35% ethanol elution part by silica gel column chromatography, performing gradient elution by using ethyl acetate-methanol-water, collecting 8 fractions A-H, performing gradient elution by using ODS column chromatography methanol-water to fraction D to obtain 9 fractions D1-D9, performing Sephadex LH-20 column chromatography to fraction D6, performing isocratic elution by using methanol-water to obtain 7 fractions D6A-D6G, and performing semi-preparative liquid chromatography to fraction D6F.

Further, the step 1 is as follows: reflux-extracting fructus Gardeniae dried material with 3-5 times of 50-80% ethanol for 1-3 times (each for 1-3 hr), mixing extractive solutions, and removing solvent under reduced pressure to obtain the total extract.

Preferably, the step 2 comprises sequentially eluting with water, 30% ethanol, 50% ethanol, 70% ethanol, and 95% ethanol, collecting eluates, respectively, and concentrating under reduced pressure until no ethanol smell exists to obtain water eluate, 30% ethanol eluate, 50% ethanol eluate, 70% ethanol eluate, and 95% ethanol eluate.

Preferably, the ethyl acetate-methanol-water gradient elution of step 3 is performed by gradient elution with (95:5:0 to 0:0:100, v/v/v); the methanol-water gradient elution is performed by gradient elution with (30: 70-50: 50, v/v); the methanol-water isocratic elution is carried out by isocratic elution with (50:50, v/v).

Specifically, the macroporous adsorption resin comprises D101 type macroporous adsorption resin, HP-20 type macroporous adsorption resin, HPD-100A type macroporous adsorption resin or HPD-300 type macroporous adsorption resin.

Further, the semi-preparative liquid chromatography conditions include: acetonitrile-water-formic acid with the volume ratio of 15-25:72-92:0.05-0.5 is taken as a mobile phase, the detection wavelength is 240-260nm, and the flow rate is 1-5 mL/min.

Preferably, the step 1 is 2 times of reflux extraction with 60% ethanol for 2 hours each time. The conditions of the semi-preparative liquid chromatography are preferably: acetonitrile-water-formic acid with the volume ratio of 18:82:0.1 is used as a mobile phase, the detection wavelength is 254nm, and the flow rate is 4 mL/min.

The invention also aims to provide the application of the compound in preparing anti-inflammatory drugs. The compound of the invention induces RAW264.7 cells to generate PGE by LPS₂Has obvious inhibiting effect.

The invention also provides a medicament for treating inflammation, which comprises the compound shown in the formula (I).

Further, the medicament comprises a therapeutically effective amount of a compound of formula (I) as described above, together with one or more pharmaceutically acceptable carriers.

Specifically, the medicament can be any one of the dosage forms in pharmaceutics, including tablets, capsules, soft capsules, gels, oral preparations, suspensions, granules, patches, ointments, pills, powders, injections, infusion solutions, freeze-dried injections, intravenous emulsions, liposome injections, suppositories, sustained-release preparations or controlled-release preparations.

Further, the pharmaceutically acceptable carrier refers to a pharmaceutical carrier conventional in the pharmaceutical field, such as: diluents, excipients, and water, and the like, fillers such as starch, sucrose, lactose, microcrystalline cellulose, and the like; binders such as cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone; humectants such as glycerol; disintegrating agents such as sodium carboxymethyl starch, hydroxypropyl cellulose, crosslinked carboxymethyl cellulose, agar, calcium carbonate and sodium bicarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as cetyl alcohol, sodium lauryl sulfate; adsorption carriers such as kaolin and bentonite; lubricants such as talc, calcium and magnesium stearate, micronized silica gel, polyethylene glycol, and the like. Other adjuvants such as flavoring agent, sweetener, etc. can also be added into the composition.

The iridoid glycoside compound is a new chemical component found in gardenia by researchers, and is found to exist stably in gardenia of each batch. The inventor utilizes physicochemical properties and modern wave spectrum means (MS, B, C, D, A, D, A,¹H-NMR、¹³C-NMR, etc.), and carrying out structural identification on the compound obtained by the separation method to confirm that the compound is a novel compound with the structure shown in the formula (I). The invention also utilizes an activity screening system such as an LPS (LPS) -induced RAW264.7 cell inflammation model and the like to carry out activity evaluation, and finds that the compound has a certain protection effect on a mouse macrophage system RAW264.7 and can obviously inhibit PGE (platelet-rich antigen)₂Showing strong anti-inflammatory action. Has good research and development prospect.

Drawings

FIG. 1 is a drawing of a compound of the present invention¹H-NMR spectrum;

FIG. 2 is a drawing of a compound of the present invention¹³C-NMR spectrum;

FIG. 3 is a DEPT-135 spectrum of a compound of the invention;

FIG. 4 is H of a compound of the present invention¹-H¹A COSY spectrum;

FIG. 5 is an HSQC spectrum of a compound of the present invention;

FIG. 6 is an HMBC spectrum of a compound of the present invention;

FIG. 7 is HR-ESI-Q-TOF-MS of a compound of the present invention;

FIG. 8 shows the main HMBC correlation and H for the compounds of the present invention¹-H¹COSY is related.

Detailed Description

The following will specifically describe the contents of the experimental examples.

It is specifically noted that similar alternatives and modifications will be apparent to those skilled in the art, which are also intended to be included within the present invention. It will be apparent to those skilled in the art that the techniques of the present invention may be implemented and applied by modifying or appropriately combining the methods and applications described herein without departing from the spirit, scope, and content of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention.

If the specific conditions are not indicated, the method is carried out according to the conventional conditions or the conditions suggested by manufacturers, and the used raw material medicines or auxiliary materials and the used reagents or instruments are the conventional products which can be obtained commercially.

EXAMPLE 1 preparation of the Compounds of the invention

(1) Reflux-extracting fructus Gardeniae dried material with 60% ethanol for 2 times (2 hr each time), mixing extractive solutions, and removing solvent under reduced pressure to obtain total extract. Dissolving the total extract in water, separating by HP-20 macroporous adsorbent resin column chromatography, sequentially eluting with water, 25% ethanol, 45% ethanol, 65% ethanol, and 90% ethanol, each gradient eluting for 4 column volumes (the same below), collecting eluates, respectively, and concentrating under reduced pressure until no alcohol smell exists to obtain water eluate, 25% ethanol eluate, 45% ethanol eluate, 65% ethanol eluate, and 90% ethanol eluate;

(2) separating the 25% ethanol elution part in the step (1) by silica gel column chromatography, eluting with ethyl acetate-methanol-water gradient (100:0: 0; 95:5: 0; 90:10: 0; 85:15: 4; 75:25:6to60:40:8,0:100:0, v/v/v), collecting 8 fractions (A-H), subjecting fraction D to ODS column chromatography methanol-water (30: 70; 35: 65; 40: 60; 45:44to50:50, v/v) gradient elution to obtain 9 fractions D1-D9 in total, subjecting fraction D6 to SephadexLH-20 column chromatography, subjecting fraction D6 3538 to methanol-water isocratic elution (50:50, v/v) to obtain 7 fractions D6A-D6G in total, subjecting fraction D6F to semi-preparative liquid chromatography to obtain the target product iridoid compound shown in the formula (I).

Wherein, the semi-preparative liquid chromatography conditions in the step (2) are as follows: phenomenex Gemini (C)₁₈5 μm,10 × 250mm), semi-preparative high performance liquid chromatography [ shimadzu, japan pump: LC-6AD (SHIMADZU, LIQUID CHROMATOGRAPH); a detector: SPD-20A (timing UV/VIS DETECTOR); a workstation: LC solution)]Acetonitrile-water-formic acid with the volume ratio of 18:82:0.1 is used as a mobile phase, the detection wavelength is 254nm, the flow rate is 4mL/min, and the retention time on the semi-prepared liquid phase is about 25.0 min.

EXAMPLE 2 preparation of Compounds of the invention

(1) Reflux-extracting fructus Gardeniae dried material with 70% ethanol for 2 times (2 hr each time), mixing extractive solutions, and removing solvent under reduced pressure to obtain total extract. Dissolving the total extract in water, separating by HP-20 macroporous adsorbent resin column chromatography, sequentially eluting with water, 30% ethanol, 50% ethanol, 70% ethanol, and 95% ethanol, collecting eluates, respectively, and concentrating under reduced pressure until no ethanol smell exists to obtain water eluate, 30% ethanol eluate, 50% ethanol eluate, 70% ethanol eluate, and 95% ethanol eluate;

(2) and (2) separating the 30% ethanol elution part obtained in the step (1) by silica gel column chromatography, performing gradient elution with ethyl acetate-methanol-water (95:5: 0; 90:10: 0; 85:15: 0; 80:20: 4; 70:30:6to60:40:8,0:100:0, v/v/v), collecting 8 fractions (A-H), performing gradient elution with ODS column chromatography methanol-water (35: 65; 40: 60; 45:44to50:50, v/v) on the fraction D to obtain 9 fractions in total of D1-D9, performing Sephadex LH-20 column chromatography on the fraction D6, performing gradient elution with methanol-water (50:50, v/v) to obtain 7 fractions in total of D6A-D6G, and performing semi-preparative liquid chromatography on the fraction D6F to obtain the target product iridoid glycoside compound shown in the formula (I).

Wherein, the semi-preparative liquid chromatography conditions in the step (2) are as follows: phenomenex Gemini (C)₁₈5 μm,10 × 250mm), semi-preparative high performance liquid chromatography [ shimadzu, japan pump: LC-6AD (SHIMADZU, LIQUID CHROMATOGRAPH); a detector: SPD-20A (science UV/VISDECTOR); a workstation: LC solution)]Acetonitrile-water-formic acid with the volume ratio of 18:82:0.1 is taken as a mobile phase, the detection wavelength is 254nm, the flow rate is 4mL/min, and the retention time on the semi-prepared liquid phase is about 25.0 min.

EXAMPLE 3 preparation of the Compounds of the invention

(1) Reflux-extracting fructus Gardeniae dried material with 50% ethanol for 2 times (2 hr each time), mixing extractive solutions, and removing solvent under reduced pressure to obtain total extract. Dissolving the total extract in water, separating by HP-20 macroporous adsorbent resin column chromatography, sequentially eluting with water, 35% ethanol, 55% ethanol, 75% ethanol, and 100% ethanol, collecting eluates, respectively, concentrating under reduced pressure until no ethanol smell exists to obtain water eluate, 35% ethanol eluate, 55% ethanol eluate, 75% ethanol eluate, and 100% ethanol eluate;

(2) separating the 35% ethanol elution part obtained in the step (1) by silica gel column chromatography, performing gradient elution with ethyl acetate-methanol-water (90:10: 0; 80:20: 0; 75:25: 0; 70:30:4to60:40:8, v/v/v), collecting 8 fractions (A-H), performing gradient elution with ODS column chromatography methanol-water (40: 60; 45:44to50:50, v/v) on fraction D to obtain 9 fractions in total of D1-D9, performing Sephadex LH-20 column chromatography on fraction D6, performing isocratic elution with methanol-water (50:50, v/v) to obtain 7 fractions in total of D6A-D6G, and performing semi-preparative liquid chromatography on fraction D6F to obtain the target product iridoid compound with the structure shown in the formula (I).

Wherein, the semi-preparative liquid chromatography conditions in the step (2) are as follows: phenomenex Gemini (C)₁₈5 μm,10 × 250mm), semi-preparative high performance liquid chromatography [ shimadzu, japan pump: LC-6AD (SHIMADZU, LIQUID CHROMATOGRAPH); a detector: SPD-20A (timing UV/VIS DETECTOR); a workstation: LC solution)]Acetonitrile-water-formic acid with the volume ratio of 18:82:0.1 is taken as a mobile phase, the detection wavelength is 254nm, the flow rate is 4mL/min, and the retention time on the semi-prepared liquid phase is about 25.0 min.

EXAMPLE 4 structural characterization of the Compounds of the invention

The compounds of the present invention are pale yellow colloidal solids. HR-ESI-MS (positive) gave M/z573.1201[ M + Na ]]⁺(calculated 573.1220) and the molecular formula C₂₅H₂₆O₁₄The unsaturation was calculated to be 13. Structural characterization of the product obtained in example 1 is carried out, as shown in FIGS. 1-8, where FIG. 1 is a representation of a compound of the invention¹H-NMR spectrum; FIG. 2 is a drawing of a compound of the present invention¹³C-NMR spectrum; FIG. 3 is a DEPT-135 spectrum of a compound of the invention; FIG. 4 is H of a compound of the present invention¹-H¹A COSY spectrum; FIG. 5 is an HSQC spectrum of a compound of the present invention; FIG. 6 is an HMBC spectrum of a compound of the present invention; FIG. 7 is HR-ESI-Q-TOF-MS of a compound of the present invention; FIG. 8 is the primary HMBC correlation sum H for a compound of the present invention¹-H¹COSY is related.

Process for preparing compounds¹H-NMR(600MHz,in CD₃OD) spectrum showing a set of trans-olefinic hydrogen signals [ delta ]_H7.56(1H, d, J ═ 15.9Hz, H-2 "), 6.29(1H, d, J ═ 15.9Hz, H-3"), a set of 1,2, 4-trisubstituted phenylcyclohydrogen signals [ δ [, δ ]_H7.05(1H,d,J＝2.0Hz,H-5″),6.95(1H,dd,J＝8.2,2.0Hz,H-9″),6.78(1H,d,J＝2.0Hz,H-8″)]Characteristic iridoid aglycon hydrogen signals [ delta ]_H7.49(1H,s,H-3)]And [ delta ]_H5.70(1H,d,J＝4.8Hz,H-1)]One sugar end hydrogen signal [ delta ]_H4.79(1H,d,J＝8.3Hz,H-1′)]And several methylene and methine hydrogen signals.¹³C-NMR(150MHz,in CD₃OD) spectrum combined with DEPT135 spectrum, showing 25 carbon signals in total, including: 8 quaternary carbon signal (. delta.)_C170.5,169.1,167.7,149.6,146.8,136.1,127.7,112.6) in which there are 3 ester carbonyl signals and 15 methine signals (. delta.) (_C153.5,147.5,147.1,123.1,116.5,115.1,114.9,100.4,96.2,77.7,75.6,74.6,71.7,47.4,34.9), and 2 methylene groups (. delta.) (delta.))_C64.7,40.1)。

¹H-¹In HCOSY spectrum, the related peaks H-1/H-9/H-5/H-6/H-7 are observed to be combined with the related peaks H-3/C-1,4,5,11, H-9/C-1,7,8,10 observed in HMBC spectrum, and combined with HSQC spectrum, the iridoid aglycone structural fragment is deduced

¹³C-NMR Signal (. delta.)_C100.4,77.7,75.6,74.6,71.7,64.7) that bind to the hydrogen signal of the carbohydrate region characteristic in the hydrogen spectrum, to assign fragments of the glucose residue of the compound. The iridoid component usually forms a glycoside at the C-1 position, combining the terminal hydrogen of the sugar with C-1 (. delta.) (_CHMBC correlation peak at position 96.2), and comparing with the literature, identifying the iridoid glycoside part structure of the compound as lipoxide. Removing the mother nucleus structure and remaining 9 carbon signals, and supposing that one C exists in the compound molecule₆-C₃A fragment of a residue. Comparing the several hydrocarbon signals with the literature, the structure of the compound is identified to contain 1 caffeoyl. In HMBC spectra, there is a significant remote correlation between H-6 ' on the glycosyl and C-1 ' carbonyl in the caffeoyl group, suggesting that the caffeoyl group is attached at C-6 ' to glucose, ultimately determining the structure of the compound.

And (4) integrating NMR spectrum information, and attributing hydrocarbon signals of the compounds. Through SciFinder Scholar network search, no relevant report is found, and the compound is a new compound named 6' -O-caffeoyllioxide.

Nuclear magnetic data for the compounds of table 1 (deuterated methanol,¹H-NMR600MHz,¹³C-NMR150MHz)

EXAMPLE 3 in vitro PGE resistance of Compounds of the formula I₂Experiment of

1. Material

1.1 pharmaceutical compounds of formula I;

1.2 cell model mouse macrophage line RAW264.7, which is from Chinese medicine science institute and provided by Jiangsu Kangyuan pharmaceutical industry GmbH of entrusting party; the culture conditions are as follows: DMEM + 10% Fetal Bovine Serum (FBS), 37 ℃, 5% CO₂。

2. Principles and methods

2.1 principle of the experiment

Lipopolysaccharide (LPS) of gram-negative outer membrane (Sigma, USA, 114M4009) is one of the most main pathogenic molecules mediating infectious inflammatory lesions, and many diseases are closely related to LPS-induced persistent subclinical inflammation. LPS is widely used to induce inflammation in animals and in cellular experiments.

Macrophages play a crucial role in the inflammatory response, and after stimulation, macrophages produce large amounts of inflammatory factors and mediators, such as: TNF-alpha, IL-1 beta, IL-6, NO and PGE₂And the like. Activation of these inflammatory factors and mediators is a key process of inflammation, and their inhibition is often used as an important index for evaluating the anti-inflammatory activity of drugs.

2.2 drug Pair secretion of PGE₂Inhibition test of

The method comprises the following steps:

(1) preparing a liquid medicine: the compound of the present invention was dissolved in 10% FBS DMEM medium to prepare a stock solution of 2 mg/ml.

(2) The experimental method comprises the following steps: the cells were digested with 0.25% pancreatin (containing 0.02% EDTA), and the cell density was adjusted to 1X 10 in 10% FBS-containing DMEM medium⁵Uniformly inoculating the seeds/ml into a 24-pore plate with each pore being 400 mu l, and placing the plate in an incubator for cultureAnd culturing for 24 hours.

Blank control group (N group): 495 μ l serum-free DMEM medium was added to each well;

vehicle group/solvent control group (RM group): 495 mul serum-free DMEM medium containing one thousandth of DMSO was added to each well;

model group (group M): add 495. mu.l of LPS 100. mu.g/ml per well;

administration sample group: 495 mul of culture medium containing different concentrations of medicaments is added into each well;

simultaneously arranging 6 multiple holes, and putting CO into the 24-hole plate after the medicine is added₂The cell culture box was incubated for 1 hour. After 1 hour, 5. mu.l of LPS (final concentration: 1. mu.g/ml) of 100. mu.g/ml was added to each well except for the blank control and the solvent control, 5. mu.l of serum-free DMEM medium was added to each well of the solvent control, and after the addition of the reagents, the 24-well plate was placed in CO₂The cell incubator was continued for 18 hours.

After 18 hours, cell culture fluid is collected, and PGE in cell supernatant is detected by ELISA method according to the kit instructions₂The content of (a).

PGE₂Inhibition (%) (model group PGE)₂Average content of-sample group PGE₂Average content of (1)/(PGE of model group)₂Average content of-solvent group PGE₂Average content) x 100%.

3. Results of the experiment

3.1 drug sample on mouse macrophage line RAW264.7 cell supernatant PGE₂Influence of (2)

The result shows that the drug sample can obviously inhibit the LPS from inducing the mouse macrophage RAW264.7PGE₂Shows strong anti-inflammatory action. Data results are shown in table 2.

TABLE 2 concentration of compound (I) on mouse macrophage line RAW264.7

Cell supernatant PGE₂Influence of (A), (B)

n＝6)

The compound in the invention is tested by a linear regression analysis method through Graphad prism7.00 analysis software and induces macrophage RAW264.7 of a mouse to secrete inflammatory mediator PGE through in vitro LPS inhibition₂Average IC of₅₀61.08. mu.M.

4. Conclusion

The compound of the invention induces mouse macrophage RAW264.7 to secrete inflammatory medium PGE by LPS₂Has remarkable inhibitory effect, shows strong anti-inflammatory effect, and can treat PGE with the increase of drug concentration₂The inhibitory effect of secretion is also increased, its IC₅₀61.08. mu.M.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (10)

1. An iridoid glycoside compound or pharmaceutically acceptable salt, tautomer and stereoisomer thereof, wherein the structure of the compound is shown as formula I:

2. a process for the preparation of a compound according to claim 1, comprising the steps of:

step 1: taking gardenia medicinal materials, carrying out reflux extraction by 50-70% ethanol, and removing a solvent to obtain a total extract;

step 2: dissolving the total extract in water, separating by macroporous adsorption resin column chromatography, eluting with water, 25-35% ethanol, 45-55% ethanol, 65-75% ethanol and 90-100% ethanol in sequence, collecting eluates respectively, and concentrating under reduced pressure to obtain a water elution part, a 25-35% ethanol elution part, a 45-55% ethanol elution part, a 65-75% ethanol elution part and a 90-100% ethanol elution part;

and step 3: separating the 25-35% ethanol elution part by using a silica gel column chromatography, performing gradient elution and collection by using ethyl acetate-methanol-water to obtain 8 fractions of A-H, performing gradient elution by using ODS column chromatography methanol-water to obtain 9 fractions of D1-D9, performing Sephadex LH-20 column chromatography to obtain 7 fractions of D6A-D6G, and performing gradient elution by using methanol-water to obtain 7 fractions of D6F by using semi-preparative liquid chromatography.

3. The preparation method according to claim 2, wherein the step 1 is to take gardenia medicinal materials, reflux-extract the gardenia medicinal materials for 1 to 3 times by 3 to5 times of 50 to 80 percent ethanol for 1 to 3 hours each time, combine the extract, and remove the solvent under reduced pressure to obtain the total extract.

4. The preparation method according to claim 2, wherein the step 2 comprises eluting with water, 30% ethanol, 50% ethanol, 70% ethanol, and 95% ethanol in sequence, collecting eluates, respectively, and concentrating under reduced pressure until no alcohol smell is produced to obtain water eluate, 30% ethanol eluate, 50% ethanol eluate, 70% ethanol eluate, and 95% ethanol eluate.

5. The method according to claim 2, wherein the ethyl acetate-methanol-water gradient elution of step 3 is a gradient elution performed at a volume ratio of 95:5:0 to 0:100: 0; the methanol-water gradient elution is that gradient elution is carried out according to the volume ratio of 30:70 to50: 50; the methanol-water isocratic elution is performed at a volume ratio of 50: 50.

6. The preparation method according to claim 2, wherein the macroporous adsorbent resin is selected from the group consisting of D101 type macroporous adsorbent resin, HP-20 type macroporous adsorbent resin, HPD-100A type macroporous adsorbent resin, and HPD-300 type macroporous adsorbent resin.

7. The method of claim 2, wherein the semi-preparative liquid chromatography conditions include: the mobile phase is acetonitrile-water-formic acid with the volume ratio of 15-25:72-92:0.05-0.5, the detection wavelength is 240-260nm, and the flow rate is 1-5 mL/min.

8. The method according to claim 7, wherein the step 1 is 2 times of reflux extraction with 60% ethanol for 2 hours;

the semi-preparative liquid chromatography conditions include: the mobile phase is acetonitrile-water-formic acid with the volume ratio of 18:82:0.1, the detection wavelength is 254nm, and the flow rate is 4 mL/min.

9. Use of a compound according to claim 1 for the preparation of an anti-inflammatory medicament.

10. A medicament comprising a compound according to claim 1.

Images